Bafna Pharmaceuticals Ltd (BAFNAPH) — Board Meeting | 11 September 2026
Bafna Pharmaceuticals held its 31st AGM on September 11, 2026 via video conference, adopting audited FY2026 financials, reappointing Director Upendar Mekala Reddy, and ratifying cost auditor fees. CEO addressed shareholder queries, and remote e-voting was extended post-meeting.
About Bafna Pharmaceuticals Ltd (BAFNAPH)
Healthcare · Pharmaceuticals · Listed on BSE
📡 Get AI alerts when BAFNAPH files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track BAFNAPH — Free💡 Ask AI about this filing
📊 More BAFNAPH filings
- Announcement — 26 September 2026Bafna Pharmaceuticals announced that its trading window will close on October 1, 2026, and remain sh...
- 🔴 Annual Report — 19 August 2026Bafna Pharmaceuticals Limited announced its 31st Annual General Meeting (AGM) to be held on Septembe...
- 🟡 Board Meeting — 13 August 2026Bafna Pharmaceuticals announced its 31st Annual General Meeting will be held on September 11, 2026, ...
- 🟡 Board Meeting — 13 August 2026Bafna Pharmaceuticals announced its 31st Annual General Meeting will be held on September 11, 2026 v...
- 🟡 Board Meeting — 11 August 2026Bafna Pharmaceuticals announced the outcome of its August 11, 2026 board meeting, approving unaudite...
🔥 Also filed on 11 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when BAFNAPH files new disclosures
Track BAFNAPH filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track BAFNAPH — FreeFree account · 2 AI queries/day